Key Takeaways
- • FORE Biotherapeutics closed a $67.4 million Series D-2 extension financing, bringing total Series D-2 capital raised to $110 million, positioning the company as a registration-stage cancer therapeutics developer.
- • The round was co-led by three major institutional investors—SR One, Medicxi, and SymBiosis—with backing from a diverse syndicate including TaiAx, LG Technology Ventures, Primer Ventures, Axil, and established healthcare investors OrbiMed Advisors, HBM Healthcare Investments, and Wellington Management.
- • The financing demonstrates sustained institutional confidence in FORE's targeted cancer therapy pipeline, with participation from both returning investors and new capital sources spanning venture, corporate, and healthcare-focused funds.
- • The upsized extension format reflects strong investor demand and validates FORE's progress toward regulatory registration, indicating material advancement in clinical or regulatory milestones.
Summary
FORE Biotherapeutics, a Philadelphia-based biopharmaceutical company focused on developing targeted therapies for cancer treatment, announced the closing of a $67.4 million Series D-2 extension financing round. This capital infusion increases the total Series D-2 funding to $110 million, underscoring robust investor conviction in the company's pipeline and commercial trajectory as it advances toward registration-stage operations.
The financing was co-led by three prominent institutional investors: SR One, Medicxi, and SymBiosis. This tri-lead structure reflects the deal's institutional caliber and suggests coordinated conviction among top-tier healthcare venture and life sciences investors. The round attracted a diverse syndicate of new investors, including TaiAx, LG Technology Ventures, Primer Ventures, and Axil, alongside continued support from existing shareholders representing multiple asset classes and geographies.
The investor roster illustrates broad-based confidence in FORE's therapeutic approach. Returning investors include OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Capital, Novartis Venture Fund, Windham Life Science Partners, Samsung, and 3B Capital. This mix spans dedicated healthcare venture firms, growth-stage generalists, large institutional asset managers, and strategic corporate investors, indicating FORE has secured backing across the full spectrum of sophisticated capital sources.
The upsized extension structure—raising additional capital beyond an initial Series D-2 close—is typically deployed when early investor demand exceeds available capacity or when company milestones warrant expanded capitalization before the next funding stage. This suggests FORE has achieved material clinical or regulatory progress that extends its runway and de-risks the path to market entry or potential exit events.
The financing was co-led by three prominent institutional investors: SR One, Medicxi, and SymBiosis. This tri-lead structure reflects the deal's institutional caliber and suggests coordinated conviction among top-tier healthcare venture and life sciences investors. The round attracted a diverse syndicate of new investors, including TaiAx, LG Technology Ventures, Primer Ventures, and Axil, alongside continued support from existing shareholders representing multiple asset classes and geographies.
The investor roster illustrates broad-based confidence in FORE's therapeutic approach. Returning investors include OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Capital, Novartis Venture Fund, Windham Life Science Partners, Samsung, and 3B Capital. This mix spans dedicated healthcare venture firms, growth-stage generalists, large institutional asset managers, and strategic corporate investors, indicating FORE has secured backing across the full spectrum of sophisticated capital sources.
The upsized extension structure—raising additional capital beyond an initial Series D-2 close—is typically deployed when early investor demand exceeds available capacity or when company milestones warrant expanded capitalization before the next funding stage. This suggests FORE has achieved material clinical or regulatory progress that extends its runway and de-risks the path to market entry or potential exit events.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.